Reinforcing an aneurysmal wall is one possible way to prevent from aneurysm rupture. We preliminarily tried focal gene transfer against the wall of experimental aneurysms to aim the transgene remodeling of aneurysmal wall. Two experimental saccular aneurysms were created on canine common carotid artery with an artificial dissecting method, which resemble clinical aneurysms. Adenovirus vector (AxCALacZ, 10 8 pfu) was slowly injected into the aneurysm cavity for over 30 minutes under the condition of intraaneurysmal flow arrest using balloon-assisted neck-plasty technique. The arteries and aneurysms were evaluated 48 hours after the transduction with X-gal staining, and J3-galactosidase expression was detected mainly in the intima in both cases. No adverse effects on the normal carotid wall and no systemic complications were observed after the procedure. This experimental study suggests the possibility of gene therapy for cerebral aneurysms.
Introduction
The main purpose of aneurysm treatment is the prevention of rupture. Therefore, we usually treat cerebral aneurysms by obliterating inflow into the aneurysmal cavity physically by aneurysmal sac embolization with platinum coils or neck-clipping. However, there are still some aneurysms which are difficult to treat due to their shape and location. Reinforcing an aneurysmal wall is one of the possible palliative treatments to prevent aneurysm rupture. Surgically, unclippable aneurysms are wrapped or coated to cover the weak dome from the outer side. This concept can be applied to an endovascular approach such as endoluminal coating from the inner side. Moreover, this therapy should be performed without stressing the aneurysmal wall like a solid embolic material, and it must be effective for a long time. For this purpose biological remodeling using gene transfer into the aneurysmal wall itself is more necessary than the implanted biomaterials. We preliminarily tried focal gene transfer against the wall of experimental saccular aneurysms for practical use.
Material and methods
Two mongrel dogs (body weight, 16 and 20 kg) were included in this experiment, which was performed according to a protocol approved by the Nagoya University Animal Care Committee. All procedures were performed with general anesthesia and sterile technique. The animals were anesthetized with intramuscular injection of ketamine hydrochloride (3 mg/kg) and intravenous injection of pentobarbital (5 mg/kg), then intubated and allowed to breathe room air spontaneously. General anesthesia was maintained with additional doses of pentobarbital as required. Two experimental saccular aneurysms were created on common carotid artery by artificial dissecting method with the aid of an operating microscope. In common carotid arteries, a small incision limited to the adventitial layer was made following placement of vascular clamps distally and proximally. Then the adventitia was dissected from the media using a thin probe passed through the adventitial incision. After sufficient dissection between the two layers, an elliptical defect with a 4-mm longitudinal extent was cut in the intima. Then the adventitial incision was tightly closed and vascular clamps were released. One week after the lesioning, aneurysmal formation was recognized in about 70% of cases I. Histopathologically, the dome of the aneurysm consisted of a layer of adventitia lined by newly formed endothelium 3 months after the creation. Such lack of a media contain-ing smooth muscle is similar to the characteristics of intracranial aneurysms. Thus, histopathological and macroscopic features of this experimental aneurysm approximate those of clinically encountered aneurysms more closely than a previous model using a sutured venous pouch 2. Three months after making the aneurysm the patency of the aneurysm and the parent artery was confirmed by angiography. Then two 4Fr. sheath introducers were inserted into both femoral arteries using the Seldinger method, and from each side two 4Fr. guiding catheters were placed in the same common carotid artery.
A microballoon catheter was navigated and positioned across the neck, and a microcatheter (FastrackerlO Boston-Scientific Corporation, Natick, MA) was introduced into the aneurysm cavity. After confirming the arrest of intraaneurysmal flow with trapping of the parent artery using the neck-remodeling technique 3 was dissolved within the 0.5 ml saline, was injected continuously into the aneurysm cavity over 30 minutes using a syringe pump. After evacuation of the remaining viral vector in the aneurysm, arterial flow was recanalized with balloon deflation ( figure 1,2) . Forty-eight hours after the transduction, animals were anesthetized and the carotid arteries involving the aneurysm were harvested immediately after perfusion with heparinized saline. The harvested arteries were washed with cold phosphate-buffered saline (PBS), fixed in 2.5% glutaraldehyde for 15 min at room temperature, and then washed three times in PBS at room temperature. Evaluation of transgene expression was performed using X-Gal staining (5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 1 mM MgC}z, and 400 I1g/ml X-Gal in PBS). The arteries were incubated with X-Gal staining solution overnight at 37°C, then rinsed in PBS and fixed in 1 % paraformaldehyde. The arteries were opened longitudinally and photographed.
The delivery target zone, an aneurysmal dome, was cross-sectioned and subsequently processed for histologic analysis. Specimens were embedded in paraffin and stained with hematoxylin and eosin, and examined by light microscopy for expression of the LacZ transgene product.
Adenovirus vectors
Adenovirus vectors expressing B-galactosidase (AxCALacZ) were used, and controlled by the CAG promoter (chicken B-actin promoter + cytomegalovirus enhancer which was kindly provided by Dr. 1. Saito (University of Tokyo, Tokyo, Japan).
Results
Gene transfer was well tolerated by both animals. No adverse effects and systemic complications were observed after the procedure. Suc-A B Figure 3 Macroscopic view of harvested vessel post X-Gal staining, A) case 1 ; B) case 2. B-galactosidase expression was detected mainly in the aneurysm cavity (arrow), but some migrations to the arterial wall close to the aneurysm were also identified. cessful gene transfer was detected in both cases ( figure 3,4) . B-galactosidase expression was detected mainly in the intima of the aneurysm, but transgene activity was heterogenous. Some migrations to the arterial wall around the aneurysm were also identified.
Abnormal intraaneurysmal thrombogenesis was not observed, and no acute inflammatory reactions were seen in the transfected arteries.
Discussion
Arterial gene transfer in experimental animals has been successfully performed using plasmid/liposomes and replication-deficient retroviruses and adenoviruses 4,5,6 . Gene transfer efficiency has generally been low with plasmid/liposomes and retroviruses whereas high transfection efficiencies have been reported with adenoviruses. Adenoviruses are easily purified, and efficiently infect many dividing and nondividing cells. Although they cause inflam-mation and their expression is transient, adenoviruses are a useful vector for gene transfer to blood vessels and potentially for gene therapy of vascular disease 5, 7, 8 . This is why we used them for this experimental study.
In vivo viral gene transfer to the arterial wall via endovascular route has been accomplished by the use of local delivery catheters such as "Transport catheter", "Channel balloon catheter", and "Hydrogel-coated balloon catheter" 4,6. But to our knowledge, there has been no delivery device suitable to the aneurysm cavity in vivo up to the present. The balloon-assisted neck-remodeling technique was invented in order to protect the coil protrusion into the parent artery in case of coil embolization of broad neck aneurysms 3. It is also effective to prevent the migration of coils owing to arrest of the intraaneurysmal flow. We applied this method to transfer the gene into the aneurysmal cavity alone.
Post-procedural pathological study showed gene delivery was accomplished using a high concentration of the viral solution. But some migrations to the arterial wall around the aneurysm was also identified due to the insufficient shelter of the orifice and too much gene solution, resulting in leakage of the gene solution around the aneurysm. Some reports of human gene therapy showed systemic shedding of adenoviral vectors and untoward vector-related side-effects. Adenoviral vectors in gene therapy in vivo would reportedly require modification to improve efficiency and minimize the toxic and inflammatory responses in patients 8. To avoid side-effects we need further consideration of the volume of the gene solution and prevention of its leakage into the aneurysm cavity.
Although another experimental study of aneurysm treatment using the molecular method demonstrates ex-vivo gene transfer into vascular smooth muscle cell grafts used as the embolic material for experimental aneurysm 9 , ours is the first preliminary report, to our knowledge, to transfer the reporter gene directly into the aneurysmal intima III VIVO model, mimicking the clinical human aneurysms.
The success of this method promises the application of biologically active substances such as tissue growth-factor promoting the thicken- ing of the aneurysmal wall. But both studies used only the reporter gene, and toward the clinical treatment of the aneurysms next thing we need to do is introduction of biologically active substances such as tissue growth-factor into the aneurysm.
Prevention from leakage of vectors and durability of effects seemed to be another point for clinical use. There seem to be many issues to be resolved.
